The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least ...

Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

We will continue to work tirelessly to improve the treatment options available ... of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription ...

17, 2024 – The FDA has approved a new treatment for persistent ... and older with moderate to severe atopic dermatitis, which is the most common type of eczema. Ebglyss may be used when ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...